South Asia Molecular Point of Care Testing (using NAAT) Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

South Asia Molecular Point of Care Testing (using NAAT) Market Size

• The South Asia molecular point of care testing (using NAAT) market size was valued at USD 412.50 million in 2024 and is expected to reach USD 940.50 million by 2032, at a CAGR of 10.8% during the forecast period
• The market growth is primarily driven by the rising burden of infectious diseases such as tuberculosis, respiratory infections, and sexually transmitted diseases, alongside government initiatives to strengthen rapid and decentralized diagnostic capabilities across the region
• Furthermore, increasing healthcare investments, technological advancements in molecular diagnostics, and growing demand for accurate, portable, and user-friendly testing solutions are positioning NAAT-based molecular PoC testing as a critical diagnostic tool. These factors are accelerating adoption across both urban and rural healthcare settings, thereby significantly boosting the industry’s growth

South Asia Molecular Point of Care Testing (using NAAT) Market Analysis

• Molecular point of care testing (using NAAT), enabling rapid, accurate, and decentralized detection of infectious diseases, is becoming a critical diagnostic tool across South Asia, particularly in addressing high disease burdens such as tuberculosis, respiratory infections, and sexually transmitted diseases
• The accelerating demand for molecular PoC testing in the region is primarily fueled by the need for timely diagnosis, growing government healthcare initiatives, and the rising availability of portable and cost-effective diagnostic devices
• India dominated the South Asia molecular PoC testing (using NAAT) market with the largest revenue share of 72.9% in 2024, supported by significant government programs for TB elimination, increasing investment in healthcare infrastructure, and the presence of leading diagnostic companies
• Bangladesh is expected to be the fastest growing markets during the forecast period, supported by expanding access to healthcare services, international collaborations for infectious disease management, and rising awareness of point of care diagnostics
• Respiratory infections testing segment dominated the South Asia molecular PoC testing (using NAAT) market with a share of 56.3% in 2024, owing to the high prevalence of these conditions, government-led screening programs, and the adoption of portable NAAT platforms such as GeneXpert for rapid and accurate diagnosis

Report Scope and South Asia Molecular Point of Care Testing (using NAAT) Market Segmentation   

South Asia Molecular Point of Care Testing (using NAAT) Market Trends

Integration of Portable Platforms and Digital Connectivity

• A significant and accelerating trend in the South Asia molecular PoC (using NAAT) market is the adoption of portable diagnostic platforms integrated with digital connectivity tools, enabling faster, more accessible, and decentralized testing
  • For instance, Cepheid’s GeneXpert Omni is designed for portability and connectivity, allowing molecular diagnostics in remote and resource-limited settings where centralized laboratories are scarce
• Digital integration in NAAT-based platforms enables features such as real-time data transmission to central databases, remote monitoring, and rapid communication of results to clinicians and public health authorities. For instance, programs using GeneXpert in India transmit TB results directly into national disease databases for faster intervention
• The combination of portable NAAT devices with cloud-based reporting enhances efficiency, supporting large-scale screening programs for TB, HIV, and respiratory infections, particularly in rural and underserved areas
• This trend towards connected, mobile, and digitally enabled testing solutions is reshaping diagnostic accessibility in South Asia. Consequently, companies such as Molbio Diagnostics are advancing handheld NAAT devices with cloud integration for real-time disease surveillance
• The demand for portable and digitally connected NAAT-based molecular PoC testing solutions is expanding rapidly across both government programs and private healthcare sectors, as healthcare systems increasingly prioritize accessibility, speed, and accuracy in diagnostics

South Asia Molecular Point of Care Testing (using NAAT) Market Dynamics

Driver

Rising Infectious Disease Burden and Healthcare Initiatives

• The growing prevalence of infectious diseases such as tuberculosis, HIV, and respiratory infections, coupled with increasing government initiatives for early detection, is a significant driver for the demand of molecular PoC (using NAAT) testing in South Asia
  • For instance, in March 2024, India’s Revised National TB Control Program expanded deployment of portable NAAT devices across rural districts, aiming to accelerate early TB diagnosis and reduce mortality rates
• As healthcare systems in South Asia work to improve access and reduce diagnostic delays, NAAT-based PoC platforms provide critical advantages including high accuracy, rapid turnaround times, and decentralized availability, surpassing traditional lab-based methods
• Furthermore, international donor funding and public-private partnerships are strengthening availability of NAAT solutions, enabling integration of these tools into national health programs for large-scale disease management
• The convenience of on-site sample-to-result testing, portability, and ability to deliver results within hours are key factors propelling adoption of NAAT-based PoC testing across both government facilities and private healthcare networks. The growing recognition of molecular PoC diagnostics as essential to public health surveillance further contributes to regional market growth

Restraint/Challenge

High Costs and Infrastructure Limitations

• Concerns surrounding the affordability of NAAT-based PoC devices and the limited laboratory infrastructure in remote areas pose significant challenges to broader adoption across South Asia. As these platforms require specialized cartridges and equipment, recurring costs can be prohibitiveFor instance, limited funding and higher test prices in low-income regions have slowed the scale-up of molecular PoC diagnostics, making governments dependent on donor programs for sustained access
• Addressing these cost and infrastructure challenges through subsidized pricing, bulk procurement, and innovations in low-cost cartridges is crucial for ensuring wider adoption. Companies such as Molbio Diagnostics emphasize affordability and portability in their platforms to appeal to resource-limited healthcare settings
• In addition, the need for consistent supply chains, reliable power sources, and skilled personnel can hinder effective deployment, particularly in rural or underserved communities. While donor support has improved access, sustainability remains a key concern once external funding declines
• Although costs are gradually decreasing and local manufacturers are emerging, the perceived expense of NAAT-based testing compared to conventional diagnostics still limits widespread uptake in certain markets. This issue is compounded by limited awareness among healthcare workers in remote areas
• Overcoming these barriers through cost reduction, infrastructure strengthening, and targeted training programs will be vital to achieving large-scale adoption and maximizing the impact of molecular PoC testing in South Asia

South Asia Molecular Point of Care Testing (using NAAT) Market Scope

The market is segmented on the basis of product, indication, end user, mode of testing, and distribution channel.

• By Product

On the basis of product, the market is segmented into instruments and consumables & reagents. The consumables & reagents segment dominated the market with the largest revenue share in 2024, driven by the recurring need for test cartridges, reagents, and kits across a wide range of NAAT platforms. As molecular point-of-care devices are increasingly deployed in hospitals, laboratories, and field programs, the demand for consumables rises proportionally with each test performed. This creates a steady revenue stream for manufacturers, as consumables must be replenished continuously, unsuch as instruments that represent one-time purchases. Moreover, the expansion of TB, HIV, and respiratory infection screening programs across South Asia further strengthens demand for reagents and cartridges.

The instruments segment is anticipated to witness the fastest growth from 2025 to 2032, fueled by rising adoption of portable and automated NAAT devices in hospitals, clinics, and rural healthcare centers. Governments and NGOs are investing in expanding diagnostic infrastructure by supplying instruments such as GeneXpert and Truenat systems to underserved areas. Technological advancements are also making devices more compact, cost-effective, and connected to digital platforms. As accessibility improves, instrument installations are expected to grow significantly, particularly in remote and decentralized healthcare settings.

• By Indication

On the basis of indication, the market is segmented into respiratory infections testing, sexually transmitted infection (STI) testing, gastrointestinal tract infections testing, and others. The respiratory infections testing segment dominated the market in 2024 with a market share of 56.3%, largely due to the high prevalence of tuberculosis, influenza, and COVID-19-related diagnostics across South Asia. Tuberculosis remains a leading health challenge in India, Bangladesh, and Pakistan, driving large-scale deployment of NAAT-based PoC platforms for rapid TB detection. Governments and international health agencies have prioritized respiratory testing through dedicated funding, ensuring strong demand for NAAT platforms. In addition, recurrent influenza outbreaks and the legacy of COVID-19 have reinforced the importance of molecular respiratory diagnostics as a routine healthcare tool.

The sexually transmitted infection (STI) testing segment is projected to witness the fastest growth rate from 2025 to 2032, driven by rising awareness and government programs targeting HIV, HPV, and chlamydia in South Asia. Increasing investment in women’s health initiatives, coupled with the growing adoption of portable NAAT platforms for on-site STI detection, is propelling this segment forward. Partnerships between global diagnostic companies and local healthcare organizations are improving access to point-of-care STI testing. The growing acceptance of rapid and discreet testing in community health settings further accelerates adoption.

• By End User

On the basis of end user, the market is segmented into laboratories, hospitals, clinics, ambulatory centers, homecare, assisted living facilities, and others. The laboratories segment held the largest market share in 2024, reflecting the continued dominance of centralized and semi-centralized diagnostic centers across South Asia. Laboratories remain the preferred setting for molecular PoC testing due to their established infrastructure, skilled personnel, and ability to handle high test volumes. Large-scale screening programs for TB and HIV are also frequently routed through laboratory networks. As governments strengthen laboratory capabilities with automated PoC NAAT platforms, this segment continues to generate the majority of revenues.

The homecare segment is expected to register the fastest growth through 2032, fueled by increasing availability of user-friendly and portable NAAT-based testing kits designed for personal use. Consumer demand for self-testing has grown significantly since the COVID-19 pandemic, driving interest in at-home molecular tests for respiratory, STI, and gastrointestinal infections. Advances in sample-to-answer devices and regulatory support for at-home testing in certain countries are expanding this market. The convenience, privacy, and rapid results offered by home-based NAAT solutions make them particularly attractive in urban and semi-urban areas.

• By Mode of Testing

On the basis of mode of testing, the market is segmented into prescription-based testing and OTC testing. The prescription-based testing segment dominated the market in 2024, as most NAAT-based molecular diagnostics in South Asia currently require physician oversight or are carried out within hospital and laboratory settings. Complex diseases such as TB and HIV, which demand confirmatory testing and physician intervention, strengthen the preference for prescription-led testing. The strong involvement of public health programs and hospitals in distributing NAAT testing further consolidates this segment’s dominance.

The OTC testing segment is projected to grow at the fastest rate from 2025 to 2032, supported by rising consumer preference for self-testing solutions and the expanding availability of NAAT kits through pharmacies and online platforms. Increasing awareness, affordability of compact devices, and demand for privacy in cases such as STI and respiratory infection testing are accelerating this trend. The convenience of walk-in purchases and home-based diagnostics is expected to drive OTC adoption significantly over the coming years.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2024, reflecting the strong role hospitals play as the central point of distribution for molecular PoC diagnostic consumables and kits. Most large-scale government procurement and patient-directed testing are coordinated through hospitals, making hospital pharmacies the largest distribution hub. Their ability to handle bulk supplies, integrate with public health initiatives, and serve both inpatients and outpatients sustains their dominance.

The online pharmacy segment is expected to be the fastest growing from 2025 to 2032, driven by the rapid digitalization of healthcare commerce in South Asia. The convenience of ordering diagnostic kits online, combined with wider geographic reach and competitive pricing, makes online channels increasingly attractive. Post-pandemic shifts in consumer behavior have normalized online purchasing for healthcare products, and governments are gradually regulating e-pharmacy models to ensure quality. This channel is set to capture significant growth, especially for OTC and home-based molecular PoC tests.

South Asia Molecular Point of Care Testing (using NAAT) Market Regional Analysis

• India dominated the South Asia molecular PoC testing (using NAAT) market with the largest revenue share of 72.9% in 2024, supported by significant government programs for TB elimination, increasing investment in healthcare infrastructure, and the presence of leading diagnostic companies
• Healthcare providers and public health authorities in India highly value the rapid turnaround, accuracy, and portability offered by NAAT-based molecular PoC testing platforms, which are essential for early detection and management of infectious diseases
• This widespread adoption is further supported by large-scale funding from national programs and international agencies, rising awareness among clinicians, and increasing integration of digital reporting and connectivity in diagnostic workflows, establishing NAAT-based PoC testing as a preferred solution for both hospital and community health settings across India

Pakistan Molecular PoC (NAAT) Market Insight

The Pakistan molecular PoC (NAAT) market is projected to grow at a notable CAGR during the forecast period, fueled by rising infectious disease burdens and government-led health initiatives. Increasing deployment of portable NAAT devices in hospitals and diagnostic centers is improving access to timely diagnosis. National programs targeting TB, hepatitis, and COVID-19 have accelerated adoption across public health facilities. Growing awareness among healthcare providers about the efficiency of NAAT testing and donor-supported programs for rural health coverage further drive the market. The demand for rapid and accurate testing solutions is fostering expansion across both hospital and community healthcare settings. In addition, rising partnerships with international diagnostic companies are facilitating technology transfer and local adoption.

Bangladesh Molecular PoC (NAAT) Market Insight

The Bangladesh molecular PoC (NAAT) market is expected to witness the fastest growth during the forecast period, supported by government health programs, donor funding, and increasing awareness of infectious disease diagnostics. TB and HIV testing initiatives are widely implemented using portable NAAT platforms, improving early detection rates. Expansion of laboratory networks and training programs for healthcare workers are enhancing market penetration. Increasing urbanization and access to healthcare facilities are contributing to higher adoption of molecular PoC devices. Furthermore, collaborations with NGOs and international health organizations are driving large-scale deployment in community health centers. The growing acceptance of rapid diagnostics in both public and private healthcare settings underpins this accelerated growth.

Nepal, Sri Lanka, and Bhutan Molecular PoC (NAAT) Market Insight

The Nepal, Sri Lanka, and Bhutan molecular PoC (NAAT) markets are gradually expanding, supported by targeted government programs for TB, HIV, and COVID-19 testing, alongside international aid and public-private collaborations. Limited but steadily improving diagnostic infrastructure, coupled with adoption of portable NAAT platforms, is increasing access to rapid testing in rural and semi-urban regions. Awareness campaigns and training of healthcare personnel are helping integrate PoC molecular testing into national healthcare systems. While the overall market share is smaller compared to India, these countries are experiencing steady growth due to ongoing healthcare initiatives. The gradual rollout of affordable devices and consumables is supporting adoption in hospitals, clinics, and community health centers. Regional collaborations and knowledge transfer from larger markets further support market expansion.

South Asia Molecular Point of Care Testing (using NAAT) Market Share

The South Asia Molecular Point of Care Testing (using NAAT) industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Danaher (U.S.)
• Meridian Bioscience, Inc. (U.S.)
• QuantuMDx Group Ltd. (U.K.)
• Binx Health, Inc. (U.S.)
• BIOMÉRIEUX (France)
• QIAGEN (Germany)
• Quidel Corporation (U.S.)
• Sysmex Corporation (Japan)
• Bio-Rad Laboratories, Inc. (U.S.)
• SEKISUI Diagnostics (Japan)
• Randox Laboratories Ltd. (U.K.)
• Seegene Inc. (South Korea)
• Grifols S.A. (Spain)
• Guangzhou Wondfo Biotech Co., Ltd. (China)
• SD Biosensor, Inc. (South Korea)

What are the Recent Developments in South Asia Molecular Point of Care Testing (using NAAT) Market?

• In May 2025, Nepal became the third country to launch a National Essential In-Vitro Diagnostics List, enhancing its health security infrastructure with support from the World Health Organization. This initiative aims to improve access to essential diagnostics, including molecular point-of-care tests, thereby strengthening the country's diagnostic capabilities
• In May 2025, Sri Lanka's Ministry of Health announced an increase in Polymerase Chain Reaction (PCR) testing in selected hospitals, particularly in urban centers and high-risk areas, in response to global concerns over a newly emerging COVID-19 variant. This move underscores the country's commitment to enhancing its diagnostic testing infrastructure
• In May 2025, the World Health Organization endorsed Truenat assays for the initial diagnosis of tuberculosis and detection of rifampicin resistance. This endorsement supports the integration of Truenat tests into national TB control programs across South Asia, facilitating improved diagnosis and treatment strategies
• In April 2025, Molbio Diagnostics introduced the Truenat HPV-HR Plus, a rapid molecular test designed for advanced cervical cancer screening. This launch aims to enhance early detection and improve patient outcomes in South Asia, where cervical cancer remains a significant health concern
• In December 2023, Molbio Diagnostics partnered with Finnish innovation leader Testi Technologies to commercialize saliva-based self-test kits. This collaboration aims to expand access to non-invasive diagnostic testing in South Asia, enhancing convenience and patient compliance

SKU-66922